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Pemphigus vulgaris (PV) is a life-threatening mucocutaneous autoimmune blistering
disease. It is often associated with autoantibodies to the desmosomal adhesion proteins
Desmoglein 3 (DSG3) and Desmoglein 1 (DSG1). Recently, auto-antigens, such as
desmocollins and others have been described in PV and in atypical pemphigus forms
such as Pemphigus Herpetiformis (PH), Pemphigus Vegetans (PVeg), and Paraneoplastic
Pemphigus (PP). Desmocollins belong to a cadherin subfamily that provides structure
to the desmosomes and play an important role in cell-to-cell adhesion. In order to
verify the pathogenic activity of anti-Desmocollin 3 (DSC3) antibodies, we developed
an active disease model of pemphigus expressing anti-DSC3 autoantibodies or anti-
DSC3 and anti-DSG3 antibodies. This approach included the adoptive transfer of DSC3
and/or DSG3 lymphocytes to Rag2−/− immunodeficient mice that express DSC3 and
DSG3. Our results show that the presence of anti-DSC3 auto-antibodies is sufficient
to determine the appearance of a pathological phenotype relatable to pemphigus, but
with features not completely super-imposable to those observed in the DSG3 active
model, suggesting that the DSC3 active model might mimic the atypical pemphigus.
Moreover, the presence of both anti-DSC3 and anti-DSG3 antibodies determines a
more severe phenotype and a slower response to prednisolone. In conclusion, we have
developed an adult DSC3 pemphigus mouse model that differs from the DSG3 model
and supports the concept that antigens other than desmogleins may be responsible for
different phenotypes in human pemphigus.
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INTRODUCTION
The term pemphigus gathers together a group of chronic life-threatening autoimmune
disorders characterized by blistering of the skin and of mucous membranes. Blistering
is caused by loss of cell-to-cell adhesion (acantholysis) determined by the presence
of autoantibodies targeting the surface of keratinocytes. Traditionally, pemphigus is
classified in two main forms: pemphigus vulgaris (PV) and pemphigus foliaceus (PF),
depending on the epidermal layer where blistering occurs. Seminal studies identified
desmosomal proteins Desmoglein3 (DSG3) and Desmoglein1 (DSG1) as the primary
targets of autoantibodies in PV (1–3). However, recent studies suggest that the presence
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of autoantibodies against DSG1 and DSG3 alone is not sufficient
to fully explain the loss of cell-to-cell adhesion observed
in pemphigus (4). Moreover, non-Desmoglein antigens and
autoantibodies have been detected in PV and other forms
of pemphigus, such as atypical pemphigus (4, 5). These
forms of pemphigus are characterized by the absence of
Desmoglein autoantibodies and by the presence of different
non-DSG autoantibodies that might act in synergy to develop
the pathological phenotype of atypical pemphigus (6). Non-
Desmoglein antigens observed in PV and in atypical pemphigus
(5), include cadherins, cholinergic receptors, mitochondrial
proteins, and members of the armadillo family of proteins. In
particular, Desmocollins that are responsible for the structure of
the desmosome (7) and play a fundamental role in cell-to cell
adhesion (8, 9) seem to be particularly relevant. Indeed, DSC1
and DSC3 auto-antibodies have been found in several forms of
atypical pemphigus, in the absence or- less frequently- in the
presence of anti-DSG autoantibodies (10, 11).
Several animal models have been made available for PV. The
first passive animal model (12) was obtained by inoculating
neonatal mice with IgG fractions obtained by patients’ sera. A
modified version of this passive transfer model was obtained
by inoculating adult mice with hybridoma cells producing
monoclonal anti-DSG3 antibodies (13). Active disease models
have been developed for PV and have shown to be useful
tools to evaluate therapeutic strategies that target Desmoglein
3-reactive T cells and B cells (13, 14). By this approach, DSG3
knockout mice were used to generate an immune response
against DSG3 and produce anti-DSG3 IgG antibodies. Adoptive
transfer of peripheral lymphocytes from Dsg3−/− mice to
immune-deficient but Desmoglein 3-expressing recipient mice
generated an artificial autoimmune state in the recipient mice
(14). This active disease model of pemphigus vulgaris has proved
to be useful to evaluate the efficacy of pharmacological reagents
as well as cell therapies to block antibody production (15).
In general, active models seem to be more representative of
pemphigus than passive models, since they allow to observe the
pathological phenotype through the entire lifespan of the animal.
To better understand the pathogenic role of non-DSG
autoantibodies, here we report the first DSC3 active pemphigus
mouse model. In addition, we present a new active model
expressing both anti-DSC3 and anti-DSG3 antibodies. We show
that DSC3 mouse recapitulates aspects of the human atypical
pemphigus, and that DSC3/DSG3 mice express a more severe
phenotype that fail to respond to systemic steroids.
METHODS
Cell Cultures
Sf9 insect cells (Gibco, Rockville, MD, USA) were cultured
in Insect-XPRESS Protein-free Insect Cell Medium with
L-Glu (Lonza, Walkersville, MD), containing streptomycin
(100µg/mL) and penicillin (100 U/mL) (Gibco, Rockville, MD,
USA), in serum free conditions (FBS, Lonza, Walkersville, MD).
Adherent cultures were maintained at 27◦C without the need
of CO2-humidified atmosphere. Sf9 cells adapted to suspension
culture were maintained on a shaker apparatus between 125 and
150 rpm in a non-humidified incubator at 27◦C.
Recombinant Protein Expression
Mouse Desmocollin 3 was expressed as 6xHis-tag fusion protein
in Sf9 insect cells as follows. Total cDNA was generated by RT-
PCR performed on total RNA extracted from mouse skin biopsy.
The extracellular portion of mDSC3 was generated by PCR using
the following primers: FW 5′-ATGGAGCACAAGAAGAAG
GTACTGA-3′ and RV 5′-AAGGATGGCCCACTTCCCAG-3′
(Figure 1A). The PCR product was subcloned in the pFastBac/C-
His TOPO vector (Bac-to-Bac C-His TOPO R© cloning and
expression Kit, Invitrogen, Carlsbad, CA) with a C-terminal
His-tag. The recombinant clones were analyzed by restriction
enzyme digestion and sequencing of the DSC3 insertion. DSC3
clones were then transformed into a competent DH10Bac E. coli
strain. Colonies that contain recombinant bacmid were verified
by PCR analysis with the pUC/M13 forward and reverse primers.
The recombinant bacmid DNA was transfected in Sf9 cells
using Cellfectine II reagent (Invitrogen, Carlsbad, CA) following
manufacturer’s instructions. Cells were incubated at 27◦C from 4
to 6 days. When cells showed signs of viral infection the medium
was collected and centrifuged, and the supernatant was stored at
4◦C as the P0 stock. After several round of infections, we collected
the P3 stock.
On the other hand, the P3 baculoviral stock for rDSG3
production was a kind gift of Dr. Amagai. This vector allows
active secretion of recombinant 6xHis-tagged protein in culture
medium and was constructed as described in Amagai et al. (14).
Protein expression was carried on in suspension condition,
in shaking flask incubated at 27◦C with shaking at 135 rpm.
2–4∗106/mL Sf9 cells were infected with concentrated P3
recombinant baculoviral stock at MOI 5.
Recombinant Protein Purification
For the rDSC3 production, the insect cells were collected by
centrifugation 120 h post-infection and resuspended in ice-cold
lysis buffer (50mM NaH2PO4, 250mM NaCl, 1mM CaCl2
with 0,1mM PMSF, 0.1% Triton-X100, 5 U/mL Benzonase, pH
7.8). The sample was centrifuged at 40,000x g for 30’ and
the supernatant was loaded on the 5mL HisTrap FF crude
column (GE Healthcare, Little Chalfont, UK) after addition of
20mMof imidazole. By Akta Prime chromatographic system (GE
Healthcare, Little Chalfont, UK), rDSC3 was purified using 10
column volume of wash buffer (containing 10mM of additional
imidazole) and a linear gradient of 16 column volume of elution
buffer (containing a total concentration of 300mM of imidazole).
In each step, 8mL fractions were collected for SDS-PAGE and
western blot analysis (Supplementary Figure 1A). The purified
protein was dialyzed with cellulose membranes (cut-off 10 kDa)
(Sigma Aldrich, Saint Louis, MO) in 50mM NaH2PO4, 250mM
NaCl, 1mMCaCl2, pH 7.8 to eliminate imidazole. Fractions with
rDSC3 were pooled, quantified and lyophilized.
The rDSG3 was purified from cell culture medium. 1 L of
medium was concentrated with ultra-filtration discs (cut-off
10 kDa) on amicon stirred cell (Millipore, Burlington, MA).
The concentrate medium was dialyzed as described before.
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FIGURE 1 | Production of mouse recombinant DSG3 and DSC3 and immunization scheme of mice. (A) Scheme of the recombinant proteins used in this study, i.e.,
the entire extracellular domains of murine DSG3 (mDSG3, 12) and murine DSC3 (mDSC3) were cloned and linked to 6xHis-Tag. (B) Detection of the recombinant
proteins in Sf9 cell lysates by immunoblot analysis using an anti-His-tag monoclonal antibody. Actin was used as loading control. (C) Immunization schemes used for
DSC3 breaking tolerance protocol in WT mice and for DSG3 in Dsg3−/− mice. CFA, Complete Freund’s Adjuvant; IFA, Incomplete Freund’s Adjuvant. (D) Indirect
Immunofluorescence of immunized animal sera on WT neonatal mouse skin sections. CNTRL: Serum from animals immunized with non-infected Sf9 cells proteins
emulsified in FCA. Scale bar: 50µm. (E) Schematic representation of the adoptive transfer protocol in mice.
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After two runs of dialysis, 10mM of imidazole was added to
the sample that was subsequently loaded in 5mL HisTrap FF
crude column. Purification and collection step were the same
performed for rDSC3.
SDS-Page and Western Blot
To verify the protein production in test expression experiment,
infected cells were harvested, washed with PBS and lysed on
ice in RIPA buffer containing protease inhibitors. 30 µg of
total protein were analyzed on polyacrylamide gels and blotted
onto nitrocellulose membranes. Blots were blocked for 1 h in
blocking buffer (5% non-fat milk in PBS/0.05% Tween20) and
incubated minimum 4h or overnight at 4◦C with the mouse
anti-6x-HisTagmonoclonal antibody (3D5; Invitrogen, Carlsbad,
CA) and anti-actin monoclonal antibody (C2; Santa Cruz
Biotechnology, Dallas, TX). Then membranes were washed in
PBS/0.05% Tween20, incubated with HRP-conjugated goat anti-
mouse antibody (B2213; Santa Cruz Biotechnology, Dallas, TX)
for 1 h at room temperature. After washing steps, membranes
were developed using the ECL chemiluminescent detection
system (Amersham Biosciences, Little Chalfont, UK).
Western blot analysis of fractions collected during rDSC3 and
rDSG3 purification was performed by loading 40 µl of samples
per each fraction (Supplementary Figures 1A,B).
Mice Immunization
B6;129X1-Dsg3tm1Stan/J and B6(Cg)-Rag2tm1.1Cgn/J adult
mice were obtained from Charles River Italia (Calco, Italy) and
maintained at the Laboratory of Animal Facility, University of
Modena and Reggio Emilia. Dsg3−/− offspring were obtained
by mating male and female Dsg3+/– mice. For induction of an
autoimmune response to murine rDSG3, mice were immunized
as illustrated in Figure 1C. 10 weeks-old Dsg3−/− mice were
primed with subcutaneous injection of 10 µg rDSG3 emulsified
in Imject Complete Freund’s Adjuvant (CFA) (Thermo Scientific,
Waltham, MA). After 1 and 2 weeks, mice were boosted
with subcutaneous injection of 10 µg rDSG3 emulsified with
Imject Incomplete Freund’s Adjuvant (FIA) (Thermo Scientific,
Waltham, MA). Then, other two injections of 10–20 µg rDSG3
were performed weekly intraperitoneally without adjuvant.
During last immunization, a blood sample was collected to
verify the presence of circulating anti-DSG3 IgG. To obtain
the reactive splenocytes, mice were sacrificed 30 days after
first immunization.
Immunization protocol leading to the loss of tolerance to
DSC3 was performed inWTmice (Figure 1C) slightly modifying
the protocol described by Hirose et al. (16). 7-weeks-old WT
mice were immunized at the hind footpad with 60 µg rDSC3
emulsified in Imject Complete Freund’s Adjuvant (CFA). Mice
were further immunized 3 and 6 weeks after initial immunization
in the same manner. During last immunization, a blood sample
was collected to verify the presence of circulating anti-DSC3 IgG.
To obtain the reactive splenocytes, mice were sacrificed 51 days
after first immunization.
Negative controls (CNTRL animals) were generated by
immunization with the sample resulting from non-infected Sf9
cells proteins emulsified in complete Freund’s adjuvant, following
the breaking tolerance protocol.
Adoptive Transfer of Splenocytes
Splenocytes were isolated from immunized Dsg3−/− or WT
mice by disrupting their spleen and lysing the erythrocytes.
Usually, the splenocytes were pooled from two or more
immunized Dsg3−/− or WT mice. 20∗106 DSC3 or DSG3-
reactive splenocytes were transferred via tail vein injection in
10–11-weeks-old Rag2−/− mice. To develop the DSC3/DSG3
mouse model, 10∗106 DSC3-reactive splenocytes and 10∗106
DSG3-reactive splenocytes were injected per mouse (Figure 1E).
Administration of Methyl-Prednisolone to
Pemphigus Model Mice
Methyl-prednisolone (m-PSL) (Solu-Medrol R©; Pfizer, Tokyo,
Japan) was given intraperitoneally at a dose of 100 mg/kg daily
(15), starting from day 7 after adoptive transfer and continued
for 4 weeks, till day 35. The mice were evaluated for 9 weeks.
Indirect Immunofluorescence
Sera of immunized mice were analyzed by indirect
immunofluorescence microscopy on cryosections of WT
murine skin. Sections were blocked with 1% bovine serum
albumin and 1% goat normal serum for 20’, and then incubated
with sera (1:50) for 1 h, and finally for 45’ with Alexa Fluor
488 anti-mouse antibody (Invitrogen Corporation, Carlsbad,
CA, USA). Fluorescent specimens were analyzed by a Confocal
Scanning Laser Microscopy (Leica TCS SP2).
Pemphigus Phenotype Scoring
To evaluate the level of disease in the pemphigus mouse models,
PV score was estimated weekly by counting the number of
affected sites (Table 1). Briefly, we slightly modified the Aoki
Ota evaluation table (17), counting a score of 1 for erosion, 0.5–
1 for hair loss, and 0.5–1 for erythema. The maximum total
scores for erosive lesions, hair loss, and erythema was 16. When
mice died, the PV scores at the time of death were used as
virtual scores thereafter. In addition to the PV score, each week
the weight of the animals was recorded in order to report the
weight loss from baseline (t = 0, corresponding to the moment
of splenocytes transfer).
Histology Analysis
For each sample a representative portion containing both
normal and lesional skin was fixed in 4% neutral buffered
formalin and paraffin embedded. Skin sections were analyzed
by hematoxylin and eosin (H&E) staining. For evaluation of
eosinophils, we performed Pagoda Red (Dylon International
LTD, England) staining (18). Samples were analyzed using a
conventional optical microscope (Zeiss Axioskope 40). Five
random microscopic fields per sample were captured at 200X
magnification. AxioVision AC imaging software was used to
acquire sample images.
Mouse DSC3 and DSG3 ELISA Assay
Not coated microtiter 96-well plates were coated with 50 µL of
4µg/mL purified murine rDSC3 or rDSG3 at 4◦C overnight.
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TABLE 1 | Summary of the frequency of the phenotypic aspects presented by the
three pemphigus mouse models.
Type of lesion Sites DSC3 (%) DSC3/DSG3 (%) DSG3 (%)
Erosion (1) Muzzle 28 83 78
Periocular region – 50 33
Periauricular region – 25 22
Back – 8 11
Chest 9 – 22
Abdomen – – –
Right foreleg 9 33 22
Left foreleg 18 25 11
Right hind leg – – 11
Left hind leg – 8 11
Tail 9 58 33
Alopecia Face (1) 91 100 100
Neck (0.5) 91 100 100
Back (1) 73 100 56
Abdomen (0.5) 100 83 100
Erythema (1) Footpad 100 100 56
Abdomen 91 83 22
In brackets the score for each symptom.
The plates were washed with washing buffer (PBS with 0.1%
Tween20, pH 7.3) and then incubated in blocking buffer (PBS
with 0.1% Tween20 and 5% BSA) at 4◦C overnight. Sample sera
were diluted 200-fold and incubated for 1 h at room temperature
on coated plates. After washing three times with washing
buffer, plates were then incubated with HRP-conjugated goat
polyclonal secondary anti-mouse IgG antibody (1:3,000; AbCam,
Cambridge, UK) for 1 h at room temperature. Three additional
wash were performed. Then the TMB substrate solution was
added and incubated for 30’ at room temperature. The reaction
was stopped by adding stop solution, containing1 mol/l H2SO4.
The absorbance was measured at 450 nm, with reference at
620 nm, by iMarkTM Microplate Absorbance Reader (BioRad,
Hercules, CA, USA). DSC3- or DSG3-immunized mouse sera
were used as positive controls, while serum from WT (not
immunized) mice was used as negative control. The index value
was defined by the following formula: index = (optical density
[OD] of tested serum – OD of negative control)/(OD of positive
control – OD of negative control)× 100. When the ELISA index
values were >200, the sera were further diluted, and the final
index values were obtained by multiplying the index values by
the dilution factor.
Ethics Statement
Animal studies and animal procedures were approved by the
Animal Welfare Committee of the University of Modena and
Reggio Emilia and carried out in accordance with the Italian
Institute of Health guidelines. The protocol was approved by the
Italian Ministry of Health.
Statistical Analysis
Data are presented as mean ± SEM, obtained from three to five
different experiments. Prism Software (Graph Pad Software V8.0)
was used to perform statistical analysis. A two-tailed unpaired
Student’s t-test was used for statistical comparisons between two
groups, while one-way or two-way ANOVAwas used for multiple
comparisons. Usually ANOVA was associated to Multiple t-test
analysis (as indicated in figure legends). A value of P < 0.05 or
less was assumed to indicate a statistically significant difference
in the compared parameters.
RESULTS
Development of Active DSC3 and
DSG3/DSC3 Pemphigus Mouse Models
Extracellular domains of the murine DSG3 and DSC3 were
cloned (Figure 1A) and both recombinant DSG3 (rDSG3)
and DSC3 (rDSC3) were produced by insect cells infected
by baculovirus as described in the methods section. In
particular, both rDSG3 and rDSC3 correspond to the entire
NH2-terminal portion of the murine protein, encompassing
all Cadherin Domains (CD1-CD2-CD3-CD4-CD5) and the
Extracellular Anchor domain, against which auto-Abs are
generated. Proteins were purified by HisTrap FF column
with a gradient from 20 to 3,000mM imidazole. For both
rDSG3 and rDSC3 no contaminating proteins were found
(Supplementary Figures 1A,B). The presence of rDSG3
and rDSC3 in the eluate was confirmed by western blot
(Figure 1B).
The protocols for immunizing Dsg3−/− mice with rDSG3
(12) and to break immunological tolerance to DSC3 in wild
type (WT) mice (modified from 16) are schematically presented
(Figure 1C). In particular, WT mice were immunized with 60
µg rDSC3 emulsified in complete Freund’s adjuvant 7 weeks
following birth. They were then boosted at weeks 10 and 13.
At week 14 mice were sacrificed, their spleen was explanted
and the presence of antibodies in their serum was evaluated
by indirect immunofluorescence using mouse WT skin as a
substrate (Figure 1D). Anti-DSG3 is present mainly in the basal
and immediately suprabasal layers of the epidermis. Anti-DSC3
display the same kind of expression, as described in literature
(19), and consistent with the pattern observed in human skin
(20). After confirming the presence of antibodies, splenocytes
were isolated from rDSG3 immunized DSG3−/− mice and from
rDSC3 immunized WT mice. To develop the DSG3 and the
DSC3 single antigen models, 20 × 106 splenocytes were injected
in Rag2−/− mice, while, to develop the mixed antigen model
(DSC3/DSG3), 10 × 106 for each type of reactive splenocytes
were injected in Rag2−/− mice (Figure 1E).
Phenotypic, Histopathological, and
Immunological Evaluation of Pemphigus
Models
Rag2−/− mice that receivedDSG3−/− splenocytes spontaneously
developed a pemphigus vulgaris phenotype, with erosions
and alopecia, as previously described (14). Rag2−/− mice
that received splenocytes deriving from WT mice immunized
with rDSC3 in association with splenocytes from DSG3−/−
mice developed a more severe phenotype, while Rag2−/−
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mice receiving only splenocytes obtained from WT animals
immunized with rDSC3 spontaneously developed features
suggestive of the human form of “atypical pemphigus.” The
phenotypic aspects expressed by the three different mouse
models are summarized in Table 1. As expected, DSG3 animals
are more prone to develop erosions and blisters in different
body areas. Interestingly all DSC3 transfused Rag2−/− mice
develop pemphigus mouse features, with erythema and alopecia.
DSC3/DSG3 model presents characteristics of both DSG3 and
DSC3 driven phenotypes. In particular, DSG3 animals exhibit
erosions, blisters and patchy hair loss on the snout, face,
chest, legs and tail. DSC3/DSG3 mice show more lesions and
alopecia on the face and in the periocular area, erosions
on the forelegs, with exacerbated erythema, while in DSC3
mice intense erythema and patchy hair loss are the main
phenotypic aspects. These mice also display crusted erosions
mainly localized around the snout and cheeks, where they
normally scratch (Figure 2A). Altogether, the two pemphigus
models reacting against DSG3 have a higher PV score, as
compared to the DSC3 mice (Figure 2B). By the analysis of
the Area Under the Curve (AUC), all treated animals have a
significantly higher PV score than animals receiving CNTRL
splenocytes. Moreover, score in DSC3 mice is statistically lower
than in DSC3/DSG3 mice, P = 0.0107 (Figure 2C). To further
characterize pemphigus mice, we evaluated the body weight over
time. DSC3/DSG3 and DSG3 mice undergo a more pronounced
weight loss, as compared to the DSC3 animals, confirming
a more severe phenotype. In particular, DSG3/DSC3 mice
experience the most relevant weight loss, reaching a plateau at
49 days after splenocyte transfer (Figure 2D). The histologic
examination revealed an extensive intraepithelial loss of cell-cell
adhesion just above the basal layers (suprabasal acantholysis)
in the epidermis and hair follicles of the two mouse models
reacting against DSG3. On the other hand, in DSC3 models,
acantholysis is visible at a lower extent (see arrows, Figure 2E).
Cleft formation between the cells surrounding the telogen club
and the basal layer of the outer root sheath epithelium (arrows)
and empty, dilated telogen hair follicles (arrows) account for
the massive alopecia observed in the three models (Figure 2E).
Only in the DSC3/DSG3 mouse model, high magnification
histological analysis revealed epidermal focal spongiosis and
some inflammatory cells infiltrating the dermis, in presence or
absence of crusted lesions (Figure 2F). Scattered neutrophils
were found in crusted lesions, but it is to be determined
if they are secondary to scratching. Finally, some occasional
eosinophils were detected by Pagoda Red staining (see arrows,
Figure 2F). The production of autoreactive IgG was analyzed 14,
28, and 63 days after splenocyte transfer (Figures 2G,H). Using
DSC3 ELISA assay, titers of DSC3 and DSC3/DSG3 antibodies
are significantly increased against CNTRL at each timepoint.
Moreover, antibody titers in DSC3 model is statistically higher
than in DSG3 mice, at each timepoint (P = 0.02) (Figure 2G).
On the other hand, by DSG3 ELISA, titers in DSC3/DSG3
and DSG3 mice are statistically increased against CNTRL at
each timepoint. Moreover, DSC3/DSG3 and DSG3 titers are
statistically different also from DSC3 at each timepoint (i.e., P =
0.0004, day 63) (Figure 2H).
Effect of Methyl-Prednisolone (m-PSL) in
the Three Pemphigus Mouse Models
In order to further characterize and compare the three
pemphigus mouse models, all animals underwent treatment
with m-PSL, a well-known glucocorticoid used in the therapy
of pemphigus. 100 mg/Kg m-PSL or PBS (Dil), as a control,
were injected intraperitoneally into Rag2−/− mice. Animals
receiving CNTRL splenocytes were used as internal control
(Supplementary Figure 2). Mice were treated daily, beginning
at day 7 after intravenous adoptive transfer of splenocytes.
Administration was continued for 4 weeks and discontinued
during the remaining 28 days follow up. To evaluate the
efficacy of the drug we measured the PV score during time
(Figures 3A,C, Supplementary Figure 2A). The DSC3 model
responds very rapidly (day 14, P = 0.048) and seems to show a
better recovery following m-PSL withdrawal (Figure 3A). On the
contrary, the other pemphigus models (DSC3/DSG3 and DSG3)
appear to be only partially responsive to m-PSL (Figures 3B,C).
Indeed, in DSC3/DSG3 model m-PSL is statistically different
from Dil only at day 14 (P = 0.025) (Figure 3B), while m-
PSL treatment is not effective in DSG3 model (Figure 3C).
PV score overtime was translated in AUC analysis. m-PSL
treatment is statistically effective in reducing AUC compared
to Dil only in DSC3 model (P = 0.01) (Figure 3G). PV score
is partially supported by the evolution of mice weight during
treatment (Figures 3D–F). In fact, this set of data shows that
only the DSC3 model is capable of recovering weight following
m-PSL administration, although no statistically significant
differences between m-PSL and Dil group were observed. To
evaluate the effect of m-PSL treatment on anti-DSC3 and
anti-DSG3 antibody production, we performed ELISA assays
during the administration and the follow-up period (Figure 3H,
Supplementary Figure 3). This analysis shows that in DSC3
ELISA, m-PSL significantly suppresses the production of
anti-DSC3 IgG starting at day 28 in DSC3 model (detailed
in Supplementary Figure 3A), and at day 63 in DSC3/DSG3
mouse model (Supplementary Figure 3B), while no significant
modulations were detected in DSG3 (Supplementary Figure 3C)
and CNTRL (Supplementary Figure 2C) treated animals,
as expected. In DSG3 ELISA, m-PSL significantly
suppresses the production of anti-DSG3 IgG at day 63
in DSC3/DSG3 and DSG3 mouse models (detailed in
Supplementary Figures 3E,F). No significant modulations
were detected in DSC3 (Supplementary Figure 3D) and CNTRL
(Supplementary Figure 2D) treated animals, as expected.
DISCUSSION
Pemphigus is a bullous disease classically associated with
autoantibodies against DSG3 and DSG1 (21). Yet, in recent years,
a number of non-desmoglein antibodies have been identified
in serum from PV patients. These autoantibodies have been
shown to play a role in keratinocyte adhesion (5, 6). At the same
time, active mouse models able to mirror the different forms
of pemphigus and in particular the variants involving the non-
desmoglein antigens are still lacking. In the present study, we
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FIGURE 2 | Phenotypic, histopathological, and immunological evaluation of the three pemphigus mouse models. (A) Phenotype of active pemphigus mouse models.
Mice injected with DSC3 autoreactive splenocytes developed crusted erosions around the snout and cheeks. Intense erythema and patchy hair loss are the main
phenotypic aspects. Animals receiving DSC3/DSG3 autoreactive splenocytes exhibit a more severe phenotype, with crusted erosions also on paws, large areas of
alopecia and exacerbated erythema. DSG3 animals perfectly reproduce the phenotype formerly published (12). (B) Phenotypic aspects were translated into PV score,
weekly evaluation, with an observational period of 63 days after splenocytes transfer into Rag2−/− mice. (n = 7–9 animals). Two-way ANOVA test between
treatments is highly significant, P < 0.0001. DSG3/DSG3 vs. CNTRL P = 0.0137, DSG3 vs. CNTRL P = 0.0293, from day 21. DSC3 vs. CNTRL P = 0.0104, from
day 35. (C) PV score overtime translated in Area Under the Curve (AUC). One-way ANOVA between treatments, P < 0.0001. All treated animals are significantly
different from CNTRL, as shown. Moreover, Unpaired t-test between DSC3 vs. DSC3/DSG3, P = 0.0107. (D) Body weight loss from the baseline (t = 0, splenocytes
infusion time) overtime (weekly evaluation, 63 days after splenocytes transfer). DSC3/DSG3 vs. CNTRL P = 0.0479, from day 49. (E) Histologic examination of active
mouse models by H&E. Scale bar: 50µm. (F) Higher histologic magnification of DSC3/DSG3 mouse skin with spongiosis (upper panel), dermal infiltrate (middle panel)
and eosinophils (Pagoda Red, lower panel). Scale bar: 50µm. (G) DSC3 ELISA. Two-way ANOVA between treatments. Only DSC3 and DSC3/DSG3 titers are
significantly modulated against CNTRL at each time-point. Moreover, DSC3 is statistically different also vs. DSG3 at each timepoint (P = 0.02). (H) DSG3 ELISA.
Two-way ANOVA between treatments. DSC3/DSG3 and DSG3 titers significantly modulated against CNTRL at each timepoint. Moreover, DSC3/DSG3 and DSG3 are
significantly different also vs. DSC3 at each timepoint (i.e., P = 0.0004, day 63). *0.05 < p < 0.01; **p < 0.01; ***p < 0.0001.
present two novel animal models of pemphigus developed by a
protocol originally established for DSG3 PV (14). In particular,
we have shown the contribution of DSC3 in the genesis of
pemphigus. To our knowledge, this is the first pemphigus model
generated by DSC3 antibodies.
In order to develop the DSC3 and the mixed DSC3/DSG3
models, Rag2−/− mice were infused with splenocytes deriving
from Dsg3−/− mice immunized against recombinant DSG3 as
described in literature (14) and/or with splenocytes deriving
from WT mice that underwent breaking of immunological
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FIGURE 3 | Effect of methyl-prednisolone (m-PSL) treatment in the three pemphigus mouse models. m-PSL was administered i.p. daily from day 7 after the adoptive
transfer to day 35. Animals were randomly assigned to the m-PSL or PBS (Dil) treatment group (n = 5–7 animals per group). PV score (A–C) and body weight
variations (D–F) were reported weekly, till day 63. For DSC3 mouse model: (A) PV score: by multiple t-test at each timepoint, m-PSL is statistically different from Dil at
day 14 (P = 0.048), day 35 (P = 0.028), day 42 (P = 0.024) and day 49 (P = 0.021); (D) Body weight loss: no statistically significant differences among m-PSL and Dil
group. For DSC3/DSG3 mouse model: (B) PV score: by multiple t-test at each timepoint, m-PSL is statistically different from Dil only at day 14 (P = 0.025); (E) Body
weight loss: no statistically significant differences among m-PSL and Dil group. For DSG3 mouse model: (C) PV score and (F) Body weight loss no statistically
significant differences among m-PSL and Dil group. (G) PV score overtime translated in Area Under the Curve (AUC). Two-way ANOVA between conditions, P <
0.0001. By Multiple t-test analysis, m-PSL group is statistically different from Dil group only in DSC3 model (P = 0.01). (H) DSC3 and DSG3 ELISA assay. Two-way
ANOVA between conditions, P < 0.0001 for DSC3 analysis and P = 0.0076 for DSG3 analysis. In DSC3 ELISA, m-PSL significantly suppressed the production of
anti-DSC3 IgG starting from day 28 in DSC3 model, and at day 63 in DSC3/DSG3 mouse model (detailed in Supplementary Figure 3). In DSG3 ELISA, m-PSL
significantly suppressed the production of anti-DSG3 IgG at day 63 in DSC3/DSG3 and DSG3 mouse models (detailed in Supplementary Figure 3). *0.05 < p <
0.01; **p < 0.01.
tolerance against DSC3. This approach was chosen since
the DSC3-null mutation results in embryonic lethality, with
most mutant embryos dying before they can implant into
the uterus (22). Moreover, DSC3fl/fl/K14-Cre conditional null
mice display very severe acantholytic phenotype (animals were
not usually maintained more than 3 months of age), and
approximately 10% of the newborn mutant mice, that developed
severe epidermal blisters, die few hours after birth (19). Thus,
immunological tolerance was broken by injecting WT mice with
a recombinant protein obtained by baculovirus corresponding to
the extracellular domain of DSC3 (Figure 1A), by modification
of the protocol set-up by Hirose et al. (16). It should be taken
into account that this kind of immunization strategy may only
lead to a partial loss of tolerance, as compared to introducing a
neo-antigen as in Dsg3−/− mice immunized against rDSG3.
Desmocollins encode N-glycosylated transmembrane
proteins that belong to the cadherin family of calcium-dependent
cell-adhesion molecules. DSC3, in particular, is expressed mainly
in the basal and first suprabasal cell layers of the skin and the
presence of anti-DSC3 antibodies has already proved to be
pathogenic (5, 6, 9, 20, 23).
Mice expressing antibodies against DSC3 started to develop
disease signs a few days following splenocytes transfer. Unlike
the DSG3 and DSC3/DSG3 models, the main features of DSC3
mice consisted of an intense erythema. Patchy hair loss and
crusted lesions appeared to be milder than those observed in
DSG3 and DSC3/DSG3 mice. The involvement of hair follicle
is due to the specific expression of DSC3 and DSG3 molecules
also in the bulge. In particular, DSC3 is the main DSC isoform
synthesized in the basal and first suprabasal cell layers of the
interfollicular epidermis and the outer root sheath of the hair
follicle (19, 24). Moreover, DSC3 is required to maintain cell
adhesion and hair follicle anchorage to the epidermis (19). DSG3
displays an expression pattern totally similar to DSC3. Indeed,
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DSG3 is not only critical for cell adhesion in the deep stratified
squamous epithelium, but also for anchoring the telogen hair to
the outer root sheath of the follicle, underscoring the importance
of desmosomes inmaintaining the normal structure and function
of hair (25). Moreover, Kock and co-workers demonstrated
that DSG3−/− animals show defective cell-cell adhesion and
hair loss (26). Lastly, Rag2−/− mice actively producing anti-
DSG3 antibodies displayed alopecia (14). All in all, the DSC3
phenotype may resemble that observed in so-called atypical
pemphigus in humans where clinical presentation is always
milder than in PV or PF (23, 27). Histologic analysis confirms
the presence of acantholysis in DSC3 mice, though to a lower
extent, as compared to the other models. The lower intensity of
the symptoms developed by DSC3 mice might depend on the
fact that DSC3 plays a major role in the desmosomes during
embryo development (22), while in the adult its role is widely
replaced by desmogleins. Moreover, it is likely that Ab titer
could be important in determining the development of the skin
manifestations. Indeed, Amagai and co-workers demonstrated
that animals with low Ab production did not develop any
pemphigus signs unless they were boosted with recombinant
DSG3 (14). Here DSC3 animal model was not boosted with
rDSC3, and, although the DSC3 Ab titer is lower than that
of anti-DSG3 Ab, it is statistically modulated overtime and in
the different models, indicating that phenotypic effects could be
ascribed to this modulation. In addition, given that cadherins are
adhesion molecules serving also as signaling mediators (28), the
main difference between our active DSC3 mouse model and the
DSC3fl/fl/K14-Cre conditional null mouse reported by Chen and
co-workers could be explained by the different signaling activated
by the presence of auto-Ab against DSC3, that is distinctive
from the complete structural lacking of DSC3 expression (19).
Future studies will evaluate the signaling activated by anti-DSC3
Auto-Abs. Lastly, DSC3 could be compensated by DSC2, which
partially overlaps with DSC3 expression (19). In any event, the
mild phenotype observed in our DSC3mousemodel is suggestive
of the human clinical findings associated with atypical pemphigus
(9). Themixed DSC3/DSG3 and DSG3mice are clinically similar,
consistent with the model described by Amagai and co-workers
(14). However, we identified distinctive histological signs in the
DSC3/DSG3 mouse model. In particular, we found occasional
dermal eosinophils and epidermal focal spongiosis. Moreover,
a mild inflammatory infiltrate was detected in the dermis, in
the presence or absence of crusted lesions. These aspects are
peculiar of the DSC3/DSG3 model, given that no significant
infiltration of inflammatory cells was observed in the early stages
of developing blisters in the DSG3 active pemphigus mouse
model (14), indicating the uniqueness of our model and a
cooperation of the different auto-Abs in the induction of the
pemphigus phenotype (5, 6). On the other hand, this might also
suggest that the role of DSC3 alone can only account for a milder
form of pemphigus.
To further validate the DSC3 model, the three groups of
animals underwent m-PSL treatment to verify and compare the
responsiveness to this drug. DSG3 and DSC3/DSG3 pemphigus
models only partially responded to therapy, while m-PSL was
very efficacious in improving the DSC3 model, as shown by
PV Score and DSC3 antibody titer. The differential response
to m-PSL suggests that every model has its specificity and that
the development of animals expressing auto-antibodies against
different antigens might indeed be useful in order to preliminary
verify which therapy might be more appropriate to target
specific forms of pemphigus, characterized by specific subsets
of autoantibodies.
The animal model presented here can open the way
to the generation of active pemphigus models based on
different antibodies.
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